Medical Articles 2/28

Posted by rob on February 28, 2007 under Uncategorized | Be the First to Comment

Allogeneic
stem-cell transplantation provides excellent results in advanced stage
chronic myeloid leukemia with major cytogenetic response to
pre-transplant imatinib therapy.

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge.
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Medical Articles 2/27

Posted by rob on February 27, 2007 under Uncategorized | Be the First to Comment

Graft-versus-leukemia in chronic lymphocytic leukemia.
Gene-Expression Analysis of Hematopoietic Progenitor Cells Identifies Dlg7 as a Potential Stem-Cell Gene.
Dual-Specificity
Phosphatase 10 Is Fused to MDS1/EVI1-Like Gene 1 in a Case of Acute
Myelogenous Leukemia with der(1)t(1;1)(p36.3;q21).
Imatinib
provides durable molecular and cytogenetic responses in a practical
setting for both newly diagnosed and previously treated chronic
myelogenous leukemia: a study in nagasaki prefecture, Japan.

Medical Articles 2/25

Posted by rob on February 25, 2007 under Uncategorized | Be the First to Comment

Dasatinib
or high-dose imatinib for chronic-phase chronic myeloid leukemia after
failure of first-line imatinib: a randomized phase-II trial.
Important therapeutic targets in chronic myelogenous leukemia.
Synthesis and inhibition of cancer cell proliferation of (1,3′)-bis-tetrahydroisoquinolines and piperazine systems.
Massive
pulmonary embolism after treatment with rFVIIa in a thrombocytopenic
patient with acute myelogenous leukemia and intractable bleeding.
Torsades de pointes associated with voriconazole use.
Adenoviral
E1B55K oncoprotein sequesters candidate leukemia suppressor
sequence-specific single-stranded DNA-binding protein 2 into aggresomes.
Monoclonal antibody-based therapeutics for leukemia.

Medical Articles 2/20

Posted by rob on February 20, 2007 under Uncategorized | Be the First to Comment

Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment.
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Why should we still care about oncogenes?
Redirecting T lymphocyte specificity by T cell receptor gene transfer – A new era for immunotherapy.
Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases.

Medical Articles 2/17

Posted by rob on February 17, 2007 under Uncategorized | Be the First to Comment

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

[Innovation
of Clinical Trials for Anti-Cancer Drugs in Japan-Proposals from
Academia with Special Reference to the Development of Novel Bcr-Abl/Lyn
Tyrosine Kinase Inhibitor INNO-406 (NS-187) for Imatinib-Resistant
Chronic Myelogenous Leukemia.]
P-glycoprotein quantitation in acute leukemia.
Initial presentation as sclerotic bone metastases in a patient with acute myelogenous leukemia.
Predicting chronic leukaemias from assessment of complete peripheral blood counts.

Medical Articles 2/14

Posted by rob on February 14, 2007 under Uncategorized | Be the First to Comment

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.

Resistance to targeted therapy in chronic myelogenous leukemia.
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.

Medical Articles 2/11

Posted by rob on February 11, 2007 under Uncategorized | Be the First to Comment

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.
Hepatic
granulomas induced by Schistosoma mansoni in mice deficient for
connexin 43 present lower cell proliferation and higher collagen
content.

Archives Are Now Moved To New Site

Posted by rob on February 10, 2007 under Uncategorized | Be the First to Comment

All of the old blog archives of CMLNewswire have been moved to our new site at
http://cmlnewswire.wordpress.com

Medical Articles 2/10

Posted by rob on under Uncategorized | Be the First to Comment

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.

Hepatic
granulomas induced by Schistosoma mansoni in mice deficient for
connexin 43 present lower cell proliferation and higher collagen
content.
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV’s model.
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Growth
factor stimulation reduces residual quiescent chronic myelogenous
leukemia progenitors remaining after imatinib treatment.
Methylation-Independent
Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in
Acute Myelogenous Leukemia with inv(16).
Changes in DNA methylation patterns in subjects exposed to low-dose benzene.
Finding co-clusters of genes and clinical parameters.
[Plasminogenesis in blood of patients with chronic myeloproliferative syndromes]

Medical Articles 2/10

Posted by rob on under Uncategorized | Be the First to Comment

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.

Hepatic
granulomas induced by Schistosoma mansoni in mice deficient for
connexin 43 present lower cell proliferation and higher collagen
content.
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV’s model.
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Growth
factor stimulation reduces residual quiescent chronic myelogenous
leukemia progenitors remaining after imatinib treatment.
Methylation-Independent
Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in
Acute Myelogenous Leukemia with inv(16).
Changes in DNA methylation patterns in subjects exposed to low-dose benzene.
Finding co-clusters of genes and clinical parameters.
[Plasminogenesis in blood of patients with chronic myeloproliferative syndromes]

Medical Articles 2/5

Posted by rob on February 5, 2007 under Uncategorized | Be the First to Comment

Reduced expression of FLIP(SHORT) in bone marrow of low risk myelodysplastic syndrome.
Synchronous occurrence of Philadelphia chromosome-positive chronic myelogenous leukemia and breast cancer.
The
farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of
the MDR1 gene product, P-glycoprotein, and demonstrates significant
cytotoxic synergism against human leukemia cell lines.
The
tyrosine-kinase inhibitor imatinib induces long-term remission in a
patient with chronic myelogenous leukemia with translocation t(4;22).
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
[The latest data on posaconazole.]
Pivanex,
a histone deacetylase inhibitor, induces changes in BCR-ABL expression
and when combined with STI571, acts synergistically in a chronic
myelocytic leukemia cell line.
A distinct epigenetic signature at targets of a leukemia protein.
Antiproliferative
and apoptotic effects of two new gold(III)
methylsarcosinedithiocarbamate derivatives on human acute myeloid
leukemia cells in vitro.
home top